List of Excipients in Branded Drug CYCLOPHOSPHAMIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hikma Pharmaceuticals USA Inc	CYCLOPHOSPHAMIDE	cyclophosphamide	0054-0382	AMMONIA
Hikma Pharmaceuticals USA Inc	CYCLOPHOSPHAMIDE	cyclophosphamide	0054-0382	BUTYL ALCOHOL
Hikma Pharmaceuticals USA Inc	CYCLOPHOSPHAMIDE	cyclophosphamide	0054-0382	FD&C BLUE NO. 1
Hikma Pharmaceuticals USA Inc	CYCLOPHOSPHAMIDE	cyclophosphamide	0054-0382	FD&C RED NO. 40

Generic Drugs Containing CYCLOPHOSPHAMIDE

Company	Ingredient	NDC	Excipient
Nexus Pharmaceuticals LLC	cyclophosphamide	14789-125	ALCOHOL
Nexus Pharmaceuticals LLC	cyclophosphamide	14789-125	MONOTHIOGLYCEROL
Nexus Pharmaceuticals LLC	cyclophosphamide	14789-125	POLYETHYLENE GLYCOL 400
Nexus Pharmaceuticals LLC	cyclophosphamide	14789-125	PROPYLENE GLYCOL

What are the Most Frequently-Used Excipients in CYCLOPHOSPHAMIDE?

# Of NDCs	Excipient
1	ACACIA
4	ALCOHOL
2	AMMONIA
4	BUTYL ALCOHOL

Cyclophosphamide Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Cyclophosphamide is a mature, multisource alkylating agent with limited active-ingredient patent protection. Commercial value is concentrated in formulation performance, hazardous-drug handling, ready-to-use presentations, pediatric administration, supply reliability, and differentiated hospital workflow. The strongest opportunities are sterile injectable products that reduce reconstitution steps and occupational exposure, not conventional composition-of-matter patents.

What is the U.S. regulatory status of cyclophosphamide?

Cyclophosphamide is an FDA-approved nitrogen mustard used in oncology and selected immune-mediated diseases. It is marketed primarily as an oral solid and as a sterile powder for injection. U.S. products include the branded Cytoxan lineage and multiple generic products approved through ANDAs or legacy applications. [1,2]

Attribute	Current commercial position
Active ingredient	Cyclophosphamide, generally supplied as cyclophosphamide monohydrate
Therapeutic class	Alkylating antineoplastic agent
Main dosage forms	Tablets and sterile powder for injection
FDA pathway	Original NDA products and generic ANDA products
Reference product	Cytoxan
Patent status	Core product and active-ingredient protection expired
Main market	Hospital oncology, hematology, transplant, rheumatology
Key formulation issue	Safe, reproducible preparation of a cytotoxic drug
Principal commercial barrier	Manufacturing controls, containment, sterility, stability, and supply reliability

Cyclophosphamide is a prodrug metabolized primarily in the liver. Its metabolites are pharmacologically active and toxic. The labeling includes warnings for myelosuppression, urotoxicity, infertility, secondary malignancy, cardiotoxicity, pulmonary toxicity, and embryo-fetal toxicity. [1]

What excipients are used in cyclophosphamide tablets and injections?

The excipient profile depends on the dosage form and manufacturer. Injectable cyclophosphamide is commonly supplied as a sterile lyophilized or powder product containing the active ingredient and a bulking, tonicity-adjusting, or stabilizing excipient. Tablet formulations use conventional pharmaceutical excipients such as lactose, starch, magnesium stearate, and related processing aids, depending on the manufacturer and market. Exact quantitative formulas should be taken from the current product label and approved regulatory dossier. [1,2]

Injectable cyclophosphamide excipient functions

Excipient category	Typical function	Commercial relevance
Mannitol or another bulking agent	Provides cake structure and improves lyophilization behavior	Can affect reconstitution, cake appearance, and vial fill
Sodium chloride or tonicity agent	Adjusts osmolality after reconstitution	Relevant for intravenous tolerability
Buffering agent	Controls pH during manufacture and storage	May affect degradation and container compatibility
Surfactant	Limits interfacial stress in some liquid systems	Potentially useful in ready-to-use or concentrated systems
Antioxidant or chelator	Controls oxidative degradation where justified	Must be supported by compatibility data
Tablet filler	Provides mass and compression properties	Important for low-dose tablet uniformity
Disintegrant	Promotes tablet breakup	Relevant to dissolution and dose consistency
Lubricant	Supports tablet manufacture	Excess levels can slow dissolution
Film coating	Improves handling, identification, and barrier properties	May improve operator handling and reduce powder shedding

The most important excipient question is not whether a formulation contains a novel ingredient. It is whether the excipient system improves product quality, preparation safety, stability, administration, or adherence without creating new toxicological or regulatory problems.

What formulations are protected by cyclophosphamide patents?

The original cyclophosphamide composition-of-matter and basic pharmaceutical-product rights are no longer commercially controlling in the United States. Cyclophosphamide was introduced decades ago, and generic competition has existed for many years. The relevant intellectual-property opportunity is therefore formulation and process differentiation.

Potentially protectable subject matter includes:

• A stable ready-to-use cyclophosphamide solution.
• A high-concentration solution with controlled precipitation risk.
• A lyophilized formulation with improved reconstitution time.
• A formulation that reduces extractables and leachables.
• A container closure system designed for cytotoxic-drug containment.
• A dose-banded presentation for common oncology regimens.
• A pediatric liquid or dispersible dosage form.
• A formulation with extended refrigerated or room-temperature stability.
• A manufacturing process that reduces degradation products.
• A closed-system transfer or administration configuration.
• A combination of formulation, device, and preparation method.

A formulation patent must show more than the substitution of one conventional excipient for another. Stronger claims would link the excipient system to measurable technical results, such as improved chemical stability, reduced reconstitution time, lower particulate formation, superior container compatibility, or reduced occupational contamination.

How strong is the cyclophosphamide patent estate?

The active-ingredient patent estate is weak because the compound is old and widely available from multiple manufacturers. The more relevant estate is product-specific and can be assessed across four layers.

IP layer	Strength for cyclophosphamide	Commercial implication
Composition of matter	Very low	Does not block generic supply
Conventional tablet formulation	Low	Routine excipient combinations are difficult to defend
Sterile injectable formulation	Moderate if supported by unexpected stability or handling data	Can support differentiated products
Device and containment system	Moderate to high if claims are technically specific	May create switching friction in hospitals
Manufacturing process	Moderate	Can protect yield, impurity control, and scale-up know-how
Method of use	Low for established uses	New dosing or combination uses may support limited rights
Trade secrets	Moderate	Valuable for lyophilization, filling, and hazardous containment

The strongest protection is likely to come from a coordinated portfolio covering formulation composition, manufacturing parameters, container closure, and administration workflow. A single broad excipient claim would face substantial validity and obviousness risk.

When does cyclophosphamide lose exclusivity?

Cyclophosphamide has already lost the exclusivity associated with its original development. The market operates through generic competition rather than an approaching loss-of-exclusivity event. There is no meaningful U.S. composition-of-matter cliff remaining.

Orange Book status

The FDA Orange Book identifies approved drug products, therapeutic equivalence information, patents, and regulatory exclusivity where applicable. For an old multisource drug such as cyclophosphamide, the commercial analysis should focus on active patents listed against specific approved products, current marketing status, and therapeutic-equivalence ratings rather than on the original molecule. [3]

A product-specific formulation patent could change the analysis if a sponsor obtains approval for a genuinely differentiated dosage form. That patent would not automatically prevent generic tablets or conventional injectable powders from remaining on the market.

Paragraph IV challenges

A conventional cyclophosphamide generic faces little strategic value in challenging an old core patent because the core rights have expired. Paragraph IV risk becomes relevant when a sponsor obtains a new formulation, device, or method-of-use patent and lists that patent in the Orange Book.

For an improved injectable product, a generic challenger could argue that:

1. The listed patent is invalid.
2. The proposed product does not infringe.
3. The patent is not properly listable.
4. The generic product has a different formulation or container closure.
5. The claimed technical effect is not adequately supported.

A formulation sponsor should expect potential Paragraph IV litigation if the product captures meaningful hospital volume or carries a premium price.

What excipient strategy offers the best commercial opportunity?

The highest-value strategy is to solve a measurable operational problem. Excipient selection should follow the intended product architecture.

1. Ready-to-use injectable solutions

A ready-to-use or pharmacy-ready solution could reduce vial manipulation, reconstitution errors, preparation time, and powder aerosolization. The formulation must control:

• Cyclophosphamide concentration.
• pH and buffer capacity.
• Degradation products.
• Precipitation during refrigeration.
• Container adsorption.
• Light sensitivity.
• Particulate generation.
• Microbial risk after opening or preparation.
• Compatibility with infusion bags and tubing.

The business case is strongest where hospitals pay for pharmacy labor, hazardous-drug controls, and faster treatment throughput. A ready-to-use product also can support premium contracting if it reduces preparation steps without compromising stability.

2. Improved lyophilized powder

A redesigned lyophilized product may be more commercially practical than a liquid. The goal would be faster and more predictable reconstitution, lower vial breakage, reduced foaming, and improved stability across shipping conditions.

A defensible formulation could combine a specific bulking agent, buffering system, and lyophilization cycle. Patent value would depend on demonstrating a result that is not predictable from standard lyophilization practice.

3. Pediatric dosage forms

Cyclophosphamide dosing is often weight- or body-surface-area-based. Tablets and injectable products can be difficult to administer to children. Opportunities include:

• A low-strength dispersible tablet.
• A unit-dose oral powder.
• A taste-masked liquid.
• A pharmacy-stable oral suspension.
• A dose-flexible multiparticulate system.

The main technical barriers are dose uniformity, chemical stability in water-containing systems, palatability, preservative selection, and safe handling by caregivers. A liquid product would also require careful assessment of accidental exposure and household contamination.

4. Dose-banded hospital presentations

Dose banding could reduce waste from single-use vials and improve pharmacy throughput. This opportunity is more commercial than patent-driven. It may involve a family of vial sizes or prefilled containers aligned with common protocol doses.

A sponsor could protect specific concentration ranges, fill volumes, container systems, and preparation methods. The practical advantage would come from procurement and workflow integration.

5. Cytotoxic containment and administration

Cyclophosphamide is a hazardous drug. NIOSH identifies hazardous-drug handling as an occupational safety issue, and USP General Chapter <800> establishes standards for receiving, storing, compounding, dispensing, administering, and disposing of hazardous drugs. [4,5]

Excipient and packaging strategy should therefore be integrated with containment. Relevant designs include:

• Low-shedding vial closures.
• Improved crimp and stopper systems.
• Prefilled syringes or infusion containers.
• Closed-system transfer compatibility.
• Low-residual-volume connectors.
• Packaging that limits leakage during transport.
• Tamper-evident secondary containment.
• Labels and preparation aids that reduce handling errors.

These features can generate commercial differentiation even when the drug itself is generic.

What manufacturing and IP barriers affect cyclophosphamide products?

Cyclophosphamide manufacturing is more difficult than a routine oral solid because the product is cytotoxic and commonly supplied as a sterile injectable. The principal barriers include:

Containment

Manufacturers need segregated handling, validated cleaning, exposure controls, and controls for airborne or surface contamination. These requirements increase capital cost and reduce the number of qualified facilities.

Sterile manufacturing

Injectable products require aseptic processing or terminal sterilization where feasible, validated container closure integrity, environmental monitoring, and control of visible and subvisible particles.

Stability

A sponsor must characterize degradation under temperature, light, humidity, agitation, freeze-thaw, and in-use conditions. Liquid products generally create more stability and microbial-control challenges than powder products.

Supply chain

Cyclophosphamide has experienced market pressure in periods of oncology-drug shortages. FDA drug-shortage records and oncology supply reports show that manufacturing interruptions, quality actions, and limited supplier capacity can affect availability. [6] Reliable supply can therefore support hospital contracting even without strong patent protection.

Analytical control

A differentiated product requires validated methods for assay, related substances, degradation products, particulate matter, sterility, endotoxins, and container compatibility. For a liquid, the impurity profile and in-use stability package are central to regulatory approval.

Which companies are competing in cyclophosphamide?

Competition is fragmented across branded and generic manufacturers. Market participants have included Baxter, Hikma, Dr. Reddy's Laboratories, Sagent Pharmaceuticals, and other generic suppliers, depending on product, strength, and market status. Product availability changes as suppliers enter, discontinue, or report manufacturing constraints. [1,2,6]

The competitive landscape is better analyzed by presentation than by molecule:

Segment	Competitive intensity	Differentiation potential
Standard tablets	High	Low
Conventional injectable powder	High to moderate	Low to moderate
Ready-to-use injectable	Lower	High
Pediatric liquid	Low	Moderate to high
Dose-banded presentations	Moderate	Moderate
Containment-enabled packaging	Low to moderate	Moderate
Stable premixed infusion	Lower	High, subject to technical feasibility

A new entrant would compete against low-cost generics in the base product but could avoid direct price comparison through pharmacy labor savings, reduced waste, supply assurance, and improved handling.

What licensing deals could support a cyclophosphamide excipient product?

Licensing opportunities are more likely to involve enabling technology than the cyclophosphamide molecule. Relevant partners include:

• A sterile injectable manufacturer with cytotoxic containment capacity.
• A contract development and manufacturing organization with lyophilization capability.
• A specialty-pharmaceutical company with oncology hospital accounts.
• A packaging company with closed-system or cytotoxic-compatible components.
• A distributor with oncology group purchasing organization access.
• A technology company with ready-to-use liquid or high-concentration formulation know-how.

A practical deal structure could combine an upfront payment, development milestones, manufacturing transfer fees, and royalties based on net sales. The licensor should retain rights to the platform technology outside cyclophosphamide where possible. The license should define ownership of formulation data, process parameters, device interfaces, stability results, and regulatory correspondence.

What FDA pathway applies to a differentiated cyclophosphamide formulation?

The pathway depends on the relationship between the new product and an approved reference product.

Product concept	Likely pathway
Conventional tablet equivalent	ANDA, subject to bioequivalence and product requirements
Conventional injectable equivalent	ANDA, subject to pharmaceutical equivalence and bioequivalence requirements
New excipient or materially different formulation	ANDA may be possible if sameness and equivalence requirements are met; otherwise 505(b)(2) may be relevant
New delivery system	Often 505(b)(2), depending on the product’s relationship to the reference
New method of use	505(b)(2) or supplemental approval, depending on the underlying product
New combination device-container system	Product-specific regulatory assessment

A 505(b)(2) strategy can be attractive for a ready-to-use product or pediatric formulation if the sponsor can rely partly on existing cyclophosphamide safety and efficacy data while generating new formulation, stability, pharmacokinetic, or usability data. [7]

A new excipient is not automatically commercially advantageous. FDA may require toxicology, compatibility, extractables and leachables, and clinical or pharmacokinetic justification depending on the proposed use and route.

What generic launch risks exist for a new cyclophosphamide product?

Generic launch risk is high for conventional products and lower for genuinely differentiated presentations.

Conventional injectable powder

A generic competitor can usually rely on established formulation principles and existing regulatory pathways. Price erosion would be substantial if the product has no workflow advantage.

Ready-to-use liquid

Risk shifts toward formulation and container-closure equivalence. A challenger may avoid a composition claim by using a different excipient system while pursuing the same clinical use. Device or packaging claims may create narrower barriers but rarely block all competing products.

Pediatric formulation

A pediatric product may have fewer direct competitors, but market size is smaller. The commercial case depends on hospital and specialty-pharmacy demand, caregiver usability, and whether payers recognize the value of the dosage form.

Method-of-use protection

Method-of-use patents are vulnerable when the use reflects established dosing practice or predictable application of known therapy. Claims should be tied to a specific dosing schedule, patient population, biomarker, or clinically demonstrated outcome.

How does cyclophosphamide compare with newer oncology drugs?

Cyclophosphamide has lower molecule-level pricing power than newer targeted therapies, antibody-drug conjugates, and biologics. It remains commercially relevant because it is used in established combination regimens, transplant protocols, conditioning regimens, and immune-mediated diseases.

Factor	Cyclophosphamide	New targeted or biologic therapy
Active-ingredient patent value	Minimal	Often substantial
Generic competition	Extensive	Limited before loss of exclusivity
Formulation opportunity	High relative to molecule value	Often secondary to biologic stability and delivery
Hospital workflow value	High	Variable
Supply-chain sensitivity	High	Variable
Premium pricing potential	Limited for standard products; higher for ready-to-use systems	Often high
Biosimilar risk	Not applicable	Relevant to biologic competitors
Main IP strategy	Formulation, device, process, trade secret	Composition, sequence, formulation, method, manufacturing

Biosimilar risk does not apply to cyclophosphamide because it is a small-molecule drug, not a biologic. The relevant competitive threat is generic substitution and supplier expansion.

What is the revenue exposure and commercial upside?

Revenue exposure depends on the product presentation and customer segment. Standard cyclophosphamide products are exposed to generic price competition and procurement tenders. A differentiated formulation can capture value through:

• Reduced pharmacy compounding labor.
• Lower hazardous-drug exposure.
• Lower vial and drug waste.
• Fewer preparation errors.
• Better inventory management.
• More predictable delivery schedules.
• Higher availability during shortages.
• Pediatric and outpatient access.
• Simplified compliance with hazardous-drug procedures.

The addressable opportunity is more likely to be a specialty hospital product than a mass-market oral generic. A sponsor should prioritize institutions with high cyclophosphamide utilization, centralized oncology pharmacies, premixed-dose demand, and documented preparation burdens.

Key Takeaways

• Cyclophosphamide has no meaningful remaining U.S. composition-of-matter exclusivity.
• Standard tablets and injectable powders are difficult to differentiate through routine excipient selection.
• The strongest opportunities are ready-to-use injectables, improved lyophilized products, pediatric formulations, and containment-compatible packaging.
• Patent protection should combine formulation, process, container closure, and administration claims.
• A 505(b)(2) pathway may be relevant for materially improved dosage forms, while conventional equivalents generally fit the ANDA framework.
• Biosimilar risk is irrelevant; generic substitution is the principal competitive risk.
• Manufacturing, sterility, cytotoxic containment, stability, and supply reliability are more important barriers than the old molecule patent estate.
• Commercial value depends on reducing hospital handling costs and improving supply performance, not on premium pricing for cyclophosphamide itself.

FAQs

Can a novel excipient create exclusivity for cyclophosphamide?

A novel excipient can support formulation patent claims and regulatory differentiation, but it does not automatically create exclusivity. The sponsor must demonstrate a technically meaningful benefit and obtain defensible claims.

Is a ready-to-use cyclophosphamide product likely to receive orphan-drug exclusivity?

No. A ready-to-use presentation normally changes delivery or handling rather than creating a new rare-disease indication. Orphan-drug exclusivity depends on the approved use and statutory criteria, not simply on formulation novelty.

Can cyclophosphamide be developed as an oral liquid?

Yes, but the product would require control of chemical stability, dose uniformity, palatability, preservative performance, microbial quality, and caregiver exposure. The formulation may be more complex than a conventional tablet or injectable powder.

What is the best patent claim for a cyclophosphamide premix?

A strong claim would connect a defined concentration, excipient system, container, storage condition, and stability result. Claims limited to a generic buffer or standard tonicity agent would face greater validity risk.

Do closed-system transfer devices create cyclophosphamide exclusivity?

A device may support separate patent rights and commercial differentiation, but it does not confer exclusivity over cyclophosphamide. The device must be technically compatible, validated for the product, and accepted within hospital compounding workflows.

References

1. U.S. Food and Drug Administration. (2024). Cyclophosphamide prescribing information. DailyMed.
2. National Library of Medicine. (2024). Cyclophosphamide drug labels and inactive ingredient information. DailyMed.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
4. National Institute for Occupational Safety and Health. (2016). NIOSH list of antineoplastic and other hazardous drugs in healthcare settings. Centers for Disease Control and Prevention.
5. United States Pharmacopeia. (2023). General Chapter <800>: Hazardous drugs: Handling in healthcare settings.
6. U.S. Food and Drug Administration. (2024). Drug shortages: Cyclophosphamide injection.
7. U.S. Food and Drug Administration. (2024). Applications covered by Section 505(b)(2).